



DFW

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of Tianmin ZHU et al.

Group Art Unit: 1615

Application No.: 10/828,474

Examiner: Thurman K. Page

Filed: April 20, 2004

Docket No.: 01855/174 (formerly AM101007)

For: WATER SOLUBLE WORTIMANNIN DERIVATIVES

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Customer Service Window
Randolph Bldg.
401 Dulany St.
Alexandria, VA 22314

Sir:

Pursuant to 37 CFR § 1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO-1449. Unless otherwise indicated herein, one copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom. The filing of this Information Disclosure Statement and the enclosed PTO Form No. 1449, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b). The paragraphs marked below are applicable. It is believed that no fees other than those indicated below are due, but authorization is hereby given to charge any additional fees due, or to credit any overpayment, to deposit account 11-0600.

This Information Disclosure Statement is being filed (a) within three months of the filing date of a national application other than a continued prosecution application under 37 C.F.R. § 1.53(d), (b) within three months of the date of entry of the national stage as set forth in 37 C.F.R. § 1.491 in an international application, (c) before the mailing date of a first Office Action on the merits in the present application, OR (d)

BEST AVAILABLE COPY

Application No. 10/828,474
Docket No. 01855/174

before the mailing of a first office action after filing of a request for continued examination. No certification or fee is required.


The references were cited in a counterpart foreign application. An English language version of the international search report is attached for the Examiner's information.

Since this application was filed after June 30, 2003, copies of U.S. references are not included.

Respectfully submitted,


KENYON & KENYON

Date: March 2, 2005


Teresa A. Lavenue
Registration No. 47,737

TAL/jw/blg

Kenyon & Kenyon
1500 K Street, N.W.
Washington, D.C. 20005
Telephone: (202) 220-4200
Facsimile: (202) 220-4201



PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO-4 TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of 1

Complete if Known

| | |
|------------------------|--------------------|
| Application Number | 10/828,474 |
| Filing Date | April 20, 2004 |
| First Named Inventor | Tianmin ZHU et al. |
| Art Unit | 1615 |
| Examiner Name | Thurman K. Page |
| Attorney Docket Number | 01855/174 |

U.S. PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|--------------------|-----------------------|--|--------------------------------|--|--|
| | | Number - Kind Code ² (if known) | | | |
| /S.F./ | | US-2003/0194749 | 10/16/2003 | Cornelia FAS et al. | p. 9, col. 1, par. 5; claim 21 |
| | | | | | |
| | | | | | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
|--------------------|-----------------------|---|--------------------------------|---|--|----------------|
| | | Country Code ³ - Number ⁴ - Kind Code ⁵ (if known) | | | | |
| /S.F./ | | WO 03/024183 | 03/27/2003 | Garth POWIS | Abstract | X |
| /S.F./ | | WO 96/01108 | 01/18/1996 | Eli LILLY & Co. | Claims 1, 5, 19 | X |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|--------------------|-----------------------|---|----------------|
| /S.F./ | | WARD et al. "Therapeutic Potential of Phosphoinositide 3-Kinase Inhibitors" <i>Chemistry and Biology, Current Biology</i> , London, GB, vol. 10, no. 3, March 2003, pages 207-213, XP002289830 ISSN: 1074-5521 page 209, column 2, paragraph 2 – page 211. | X |
| /S.F./ | | NEWTON, "Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors" <i>Expert Rev. Anticancer Ther.</i> , vol. 4, 2004, pages 105-128, XP008041405 page 109, column 2, page 119, column 2. | X |
| /S.F./ | | THANOU et al. "Polymer-protein and polymer drug conjugates in cancer therapy" <i>Current Opinion in Investigational Drugs</i> , vol 4, no. 6, pages 701-709, XP008041394 page 704, page 706, column 2. | |
| /S.F./ | | LUO et al. "Targeting the PI3K-Akt pathway in human cancer: Rationale and promise" <i>Cancer Cell</i> , Vol. 4, October 2003, pages 257-262, XP008041402 page 260; table 1. | |

Examiner Signature

/Shahrzad Farzaneh/

Date Considered

12/06/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.